ALYFTREK's Patent Shield Extended: FDA Calls for Challenges
Published Date: 2/13/2026
Notice
Summary
The FDA has set the official review period for ALYFTREK, a new drug, so its patent holder can apply for extra patent time. This helps the company protect their invention longer, potentially delaying generic competition and affecting drug prices. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they have until April or August 2026 to speak up.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Drug patent review period set
The FDA found that ALYFTREK had a regulatory review period of 5,335 days (5,102 days testing phase and 233 days approval phase). The testing phase began May 15, 2010; the new drug application was submitted May 2, 2024; and FDA approved the application on December 20, 2024. The applicant is seeking 1,826 days of patent term extension, and FDA’s determination establishes the maximum potential length of a patent extension.
Public comment and petition windows
Anyone who thinks the published dates are wrong can submit comments requesting a redetermination by April 14, 2026. Any interested person may petition FDA about whether the applicant acted with due diligence during the regulatory review period by August 12, 2026. Instructions for electronic and written submissions are provided in the notice.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-02967 — Agency Information Collection Activities: Submission for OMB Review; Comment Request
The Centers for Medicare & Medicaid Services (CMS) wants your thoughts on their plan to keep collecting important info from the public. If you or your group deal with Medicare or Medicaid, this affects you! You’ve got until March 16, 2026, to share your ideas on how to make this process easier and better, with no new costs announced.
Next: 2026-02969 — Notice of Petition for Extension of Waiver of Compliance
The Association of American Railroads (AAR) asked the Federal Railroad Administration (FRA) to extend a break from some air brake maintenance rules for certain electronic brake systems. This means trains using these brakes can wait longer between checkups, thanks to a strong safety record. If you want to share your thoughts, make sure to comment by March 16, 2026!